Tags

Type your tag names separated by a space and hit enter

The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
Clin Invest Med. 1987 Jul; 10(4):309-15.CI

Abstract

The treatment of acromegaly is not optimal at present, since many patients have continued growth hormone hypersecretion. We report the acute effects of a cyclic octapeptide analogue of somatostatin, SMS 201-995 (Sandoz) in 9 nondiabetic, acromegalic patients between the ages of 30 and 74. We report potent and prolonged dose-dependent effects to suppress growth hormone secretion. A single 50 micrograms dose of SMS 201-995 inhibited growth hormone concentration rapidly within 15 minutes, with maximal effect in 75 minutes. Maximal inhibition was of the order of 80%, with absolute concentrations under 2 micrograms/L for about 6 hours in 5 of 7 patients. Growth hormone concentrations remained significantly suppressed below placebo control for up to 24 hours after a single dose of SMS 201-995, but the inhibitory effects on insulin and C-peptide concentrations were limited to 2 hours. The effects on glucagon secretion were minimal, and also evident for only 2 hours. Mild transient postprandial elevations of plasma glucose and FFA were documented. No adverse effects were noted; routine hematology, biochemistry, and vital signs were not altered. Thus SMS 201-995, with preferential effects at the pituitary somatotroph, holds considerable promise as an attractive and viable alternative for treatment of acromegaly.

Authors+Show Affiliations

Department of Medicine, Toronto General Hospital, University of Toronto, Ontario.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2888554

Citation

George, S R., et al. "The Somatostatin Analogue SMS 201-995 in Acromegaly: Prolonged, Preferential Suppression of Growth Hormone but Not Pancreatic Hormones." Clinical and Investigative Medicine. Medecine Clinique Et Experimentale, vol. 10, no. 4, 1987, pp. 309-15.
George SR, Hegele RA, Burrow GN. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones. Clin Invest Med. 1987;10(4):309-15.
George, S. R., Hegele, R. A., & Burrow, G. N. (1987). The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones. Clinical and Investigative Medicine. Medecine Clinique Et Experimentale, 10(4), 309-15.
George SR, Hegele RA, Burrow GN. The Somatostatin Analogue SMS 201-995 in Acromegaly: Prolonged, Preferential Suppression of Growth Hormone but Not Pancreatic Hormones. Clin Invest Med. 1987;10(4):309-15. PubMed PMID: 2888554.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones. AU - George,S R, AU - Hegele,R A, AU - Burrow,G N, PY - 1987/7/1/pubmed PY - 1987/7/1/medline PY - 1987/7/1/entrez SP - 309 EP - 15 JF - Clinical and investigative medicine. Medecine clinique et experimentale JO - Clin Invest Med VL - 10 IS - 4 N2 - The treatment of acromegaly is not optimal at present, since many patients have continued growth hormone hypersecretion. We report the acute effects of a cyclic octapeptide analogue of somatostatin, SMS 201-995 (Sandoz) in 9 nondiabetic, acromegalic patients between the ages of 30 and 74. We report potent and prolonged dose-dependent effects to suppress growth hormone secretion. A single 50 micrograms dose of SMS 201-995 inhibited growth hormone concentration rapidly within 15 minutes, with maximal effect in 75 minutes. Maximal inhibition was of the order of 80%, with absolute concentrations under 2 micrograms/L for about 6 hours in 5 of 7 patients. Growth hormone concentrations remained significantly suppressed below placebo control for up to 24 hours after a single dose of SMS 201-995, but the inhibitory effects on insulin and C-peptide concentrations were limited to 2 hours. The effects on glucagon secretion were minimal, and also evident for only 2 hours. Mild transient postprandial elevations of plasma glucose and FFA were documented. No adverse effects were noted; routine hematology, biochemistry, and vital signs were not altered. Thus SMS 201-995, with preferential effects at the pituitary somatotroph, holds considerable promise as an attractive and viable alternative for treatment of acromegaly. SN - 0147-958X UR - https://www.unboundmedicine.com/medline/citation/2888554/The_somatostatin_analogue_SMS_201_995_in_acromegaly:_prolonged_preferential_suppression_of_growth_hormone_but_not_pancreatic_hormones_ DB - PRIME DP - Unbound Medicine ER -